TORONTO, ON--(Marketwired - March 01, 2016) -


PharmaCan Capital Corp. (TSX VENTURE: MJN) ("PharmaCan") is pleased to announce that In the Zone Produce ("ITZ") has received notice from Health Canada confirming the renewal of its MMPR license. The renewal of ITZ's license is valid through February 26th 2017.

Additionally the Whistler Medical Marijuana Company ("WMMC") has received notice from Health Canada confirming the amendment to its license to permit the activity of the sale of fresh marijuana and cannabis oil.

About PharmaCan Capital Corp.

PharmaCan is a company in the business of investing in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's MMPR. PharmaCan has a diversified portfolio of investments including investments in 5 of the 29 companies licensed by Heath Canada to produce medical marijuana. PharmaCan's 5 investments includes 4 of the 23 companies that are listed on Heath Canada's website as licensed to produce and sell medical marijuana as well as another 2 of the 7 companies that are listed on Health Canada's website as licensed to produce and sell medical marijuana.

About Whistler Medical Marijuana

WMMC, based in Whistler, British Columbia, received its original MMPR license in February 2014. The Fraser Valley Organic Producers Association certifies WMMC as organic. WMMC currently operates out of a 12,500 square foot facility that it owns. It has negotiated an option to purchase the remainder of the units in its building, which when exercised upon, would increase the total facility size to 33,000 square feet. PharmaCan has a 21.4% ownership interest in WMMC.

About In The Zone Produce

In the Zone is a Licensed Producer of medical marihuana under Canada's MMPR program. Its facility resides on a 14-acre parcel of land owned by PharmaCan Capital in the Okanagan Valley in British Columbia.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Investor & Media Relations

Paul Rosen
PharmaCan Capital Corp.
Phone: (416) 504-0004